At BIO International Convention in Boston, biotech ambition turns into partnership and progress. This year, Leiden Bio Science Park joined the Dutch...

Professor Bart Roep of LUMC has received a €2.5 million ERC Advanced Grant to develop a potential cure for type 1 diabetes by creating immune-resistant insulin-producing cells. His research focuses on reducing beta cell stress and using targeted drug delivery to prevent immune system attacks.

We recently hosted Tjerk Opmeer from the Ministry of Economic Affairs at Leiden Bio Science Park to share insights into building a shared investment...

A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free...

The first Works Council Community meeting at Leiden Bio Science Park tackled workplace conduct and culture through honest, practical dialogue. With HR and legal experts in the room, the session marked the start of a collaborative effort to foster safer, more respectful workplaces.

EMA visited Leiden Bio Science Park to explore how regulatory tools can better support early-stage innovation. The visit connected EMA representatives with local leaders across academia, investment, and biotech development for a forward-looking exchange on speeding therapies to patients.

A joint effort between Leiden University's Professor Ubbink's lab and ZoBio's Assay Development and Screening team has advanced fragment-based drug...

Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU...

Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine...